Current Edition:
 
|
Table of Contents
Editor's Note
Neil Love, MD |
| |
 |
ATAC trial: Results and implications for clinical practice |
| |
Mechanism of action of fulvestrant, an estrogen receptor downregulator |
| |
Fulvestrant: Efficacy and tolerability |
| |
Clinical trials of fulvestrant |
| |
Management of patients with HER2-positive metastatic breast cancer |
| |
Duration of trastuzumab therapy |
| |
References on fulvestrant (Faslodex®) |
| |
|
| Eric P Winer, MD |
|
Quality of life considerations in choosing treatments for metastatic disease |
| |
Use of capecitabine in clinical practice |
| |
Patients' preference for oral chemotherapy |
| |
First-line chemotherapy after adjuvant anthracycline-containing regimens |
| |
Trastuzumab alone and in combination with chemotherapy |
| |
Therapeutic strategies after progression on trastuzumab |
| |
Communication and the patient-physician relationship |
| |
References on quality of life and decision-making in metastatic breast cancer |
| |
|
|
| Aman Buzdar, MD |
|
Efficacy and tolerability of anastrozole in the ATAC trial |
| |
Effect of anastrozole on bone density: Monitoring and interventional strategies |
| |
Clinical implications of the early ATAC trial results |
| |
Adjuvant anastrozole in women receiving chemotherapy |
| |
Potential of anastrozole for chemoprevention |
| |
Neoadjuvant clinical trial of capecitabine and docetaxel |
| |
Clinical trials of neoadjuvant therapy |
| |
Clinical trial of FEC/paclitaxel with or without trastuzumab as neoadjuvant therapy |
| |
References on aromatase inhibitors in the treatment of breast cancer |
| |
|
|
Nicholas J Robert, MD
|
Clinical trials of trastuzumab with taxane/platinum salt combinations |
| |
Clinical trial BCIRG 006 of adjuvant trastuzumab |
| |
First-line therapy for HER2-positive metastatic breast cancer |
| |
Duration of trastuzumab use |
| |
Use of trastuzumab for patients who received ACT adjuvant therapy |
| |
Switching patients from adjuvant tamoxifen to anastrozole |
| |
References on trastuzumab plus taxane and/or platinum salt regimens |
|
|
|
| Current Patterns of
Breast Cancer Management: |
| |
| 19th Annual Miami Breast Cancer Conference |
|
|
